Program
Octreotide
Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.
Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.
Drug pageOctreotide: every studyMany companies study it; this page follows only the 30 they lead. All 121 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 210 open or running | phase 4since Dec 17, 2002 | Nov 2, 1999 | none ahead |
| Keenova Therapeuticsits history only | 40 open or running | phase 3since Sep 30, 2008 | Sep 30, 2008 | none ahead |
| Chiesi Farmaceuticiits history only | 30 open or running | phase 3since Aug 5, 2011 | Aug 5, 2011 | none ahead |
| Ambrilia Biopharmaits history only | 10 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Dauntless Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 17, 2017 | Jan 17, 2017 | none ahead |
Also a collaborator on its studies: Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Nov 2, 1999.
- Sep 6, 2006Phase 3 study in AcromegalyNovartis · NCT00372697 · 28 enrolled · Italy
- Sep 13, 2006Phase 4 study in AcromegalyNovartis · NCT00376064 · 20 enrolled · Germany
- Dec 21, 2007Phase 1 study in Irritable Bowel SyndromeNovartis · NCT00584298 · 50 enrolled · United States, Canada, Sweden and more
- Dec 21, 2007Phase 3 study in Colorectal NeoplasmsNovartis · NCT00582426 · 139 enrolled · Brazil
- Mar 21, 2008Ambrilia Biopharma’s first study: phase 3 study in AcromegalyNew to Ambrilia BiopharmaAmbrilia Biopharma · NCT00642421 · 40 enrolled · United States, Belarus, Hungary and more
- May 15, 2008Phase 3 study in Carcinoid TumorNovartis · NCT00690430 · 186 enrolled · United States, Argentina, Austria and more
- Sep 30, 2008Keenova Therapeutics’ first study: phase 3 study in AcromegalyNew to Keenova TherapeuticsKeenova Therapeutics · NCT00765323 · 169 enrolled · United States, Czech Republic, Germany and more
- Apr 20, 2009Phase 2 study in Serotonin SyndromeKeenova Therapeutics · NCT00884715 · 10 enrolled · United States
- May 26, 2009Phase 2 study in AcromegalyKeenova Therapeutics · NCT00913055 · 34 enrolled
- Feb 10, 2011Phase 3 study in AcromegalyKeenova Therapeutics · NCT01295060 · 12 enrolled · United States
- Aug 5, 2011Chiesi Farmaceutici’s first study: phase 3 study in AcromegalyNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT01412424 · 155 enrolled · United States, Germany, Hungary and more
- Jan 28, 2016Phase 3 study in AcromegalyChiesi Farmaceutici · NCT02685709 · 146 enrolled · United States, Austria, France and more
- Jan 17, 2017Dauntless Pharmaceuticals’ first study: phase 1 study in Healthy Volunteer StudyNew to Dauntless PharmaceuticalsDauntless Pharmaceuticals · NCT03031535 · 32 enrolled · United States
- Aug 10, 2017Phase 3 study in AcromegalyChiesi Farmaceutici · NCT03252353 · 56 enrolled · United States, Australia, Bulgaria and more
TargetBeta
“Somatostatin receptor agonist”ChEMBL 37, by rule
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03252353Acromegaly · United States, Australia, Bulgaria and more | 3 | UNKNOWN | Chiesi Farmaceutici | Jun 13, 2019 | 56 |
| NCT03031535Healthy Volunteer Study · United States | 1 | Completed | Dauntless Pharmaceuticals | Mar 2017 | 32 |
| NCT02685709Acromegaly · United States, Austria, France and more | 3 | Completed | Chiesi Farmaceutici | Oct 2020 | 146 |
| NCT01412424Acromegaly · United States, Germany, Hungary and more | 3 | Completed | Chiesi Farmaceutici | May 2014 | 155 |
| NCT01295060Acromegaly · United States | 3 | Terminated | Keenova Therapeutics | Apr 2012 | 12 |
| NCT00913055Acromegaly | 2 | Completed | Keenova Therapeutics | May 2007 | 34 |
| NCT00884715Serotonin Syndrome · United States | 2 | Terminated | Keenova Therapeutics | Nov 2011 | 10 |
| NCT00765323Acromegaly · United States, Czech Republic, Germany and more | 3 | Terminated | Keenova Therapeutics | Feb 2011 | 169 |
| NCT00690430Carcinoid Tumor · United States, Argentina, Austria and more | 3 | Completed | Novartis | Apr 2012 | 186 |
| NCT00642421Acromegaly · United States, Belarus, Hungary and more | 3 | Terminated | Ambrilia Biopharma | Aug 2009 | 40 |
| NCT00584298Irritable Bowel Syndrome · United States, Canada, Sweden and more | 1 | Completed | Novartis | Apr 2009 | 50 |
| NCT00582426Colorectal Neoplasms · Brazil | 3 | Completed | Novartis | Sep 2010 | 139 |
| NCT00376064Acromegaly · Germany | 4 | Completed | Novartis | Jan 2010 | 20 |
| NCT00372697Acromegaly · Italy | 3 | Completed | Novartis | Oct 2007 | 28 |
| NCT00332969Thymoma · Germany | 2 | Completed | Novartis | Oct 2010 | 25 |
| NCT00332696Peritoneal Neoplasms · France | 2 | Completed | Novartis | Sep 2008 | 64 |
| NCT00241020Carcinoma, Hepatocellular | 3 | Completed | Novartis | Oct 2005 | 270 |
| NCT00242541Acromegaly · Mexico | 4 | Terminated | Novartis | Aug 2005 | 50 |
| NCT00225979Acromegaly | 3 | Completed | Novartis | Mar 2005 | 100 |
| NCT00171886Acromegaly · Spain | 4 | Completed | Novartis | May 2006 | 20 |
| NCT00171613Sexual Infantilism | 4 | Completed | Novartis | Oct 2005 | 32 |
| NCT00170742Disease · Switzerland | 3 | Terminated | Novartis | May 2006 | 17 |
| NCT00166725Prostatic Neoplasms · Italy | 2 | Completed | Novartis | 40 | |
| NCT00128232Acromegaly | 3 | Completed | Novartis | Aug 2004 | 100 |
| NCT00094146Obesity · United States | 2 | Completed | Novartis | 160 | |
| NCT00076362Obesity · United States | 4 | Completed | Novartis | Jul 2005 | 60 |
| NCT00050635Neoplasms · United States | 4 | Completed | Novartis | 150 | |
| NCT00006269Colorectal Neoplasms · United States | 3 | Terminated | Novartis | Dec 1999 | 89 |
| NCT00002253Diarrhea · United States | – | Completed | Novartis | ||
| NCT00002252Diarrhea · United States | – | Completed | Novartis |
How it is read
Names in the registry
- “Octreotide”, 9 entries
- “Sandostatin LAR Depot”, 3 entries
- “Octreotide LAR”, 3 entries
- “Sandostatin LAR”, 3 entries
- “Octreotide capsules”, 2 entries
Conditions, from the studies’ own filings
- Acromegaly, 17 studies
- Obesity, 2 studies
- Diarrhea, 2 studies
- Malignant Carcinoid Syndrome, 1 study
- Thymoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.